Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behcet Disease: A 2-year Follow-up Study
Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behcet Disease: A 2-year Follow-up Study
复制标题
英夫利昔单抗对白塞病相关难治性葡萄膜视网膜炎早期缓解诱导的疗效：一项 2 年随访研究
DOI：
10.1080/09273948.2016.1239746
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Nakamura T.
中科院分区：
文献类型：
--
作者：
Keino H;Okada AA;Watanabe T;Nakayama M;Nakamura T.
目的：比较英夫利昔单抗(ifliximab，IFX)对Behçet病(BD)短病程(≤18个月，n=6)和长病程(18个月，n=7)难治性葡萄膜视网膜炎的疗效。方法：回顾分析13例BD患者用IFX治疗24个月的临床资料。两组的视网膜和视盘血管渗漏评分也都有所下降，但短期组明显更低。2岁时最佳矫正视力(BCVA)在1.0或以上者，短期组为100%，长期组为21%。结论：在BD患者中，使用IFX诱导早期缓解对于减少背景血管渗漏和维持良好视力是更有效的。
Purpose: To compare the efficacy of infliximab (IFX) on refractory uveoretinitis between Behçet disease (BD) patients with short duration (≤18 months,n= 6) versus long duration (>18 months,n= 7) of their ocular disease.Methods: Records of 13 BD patients treated with IFX for 24 months were retrospectively reviewed.Results: Frequency of ocular attacks decreased with IFX treatment in both groups, with no significant difference. Retinal and disc vascular leakage scores also decreased in both groups, however was significantly lower in the short-duration group. Percentage of eyes with a best-corrected visual acuity (BCVA) of 1.0 or better at year 2 was 100% in the short-duration and 21% in the long-duration group.Conclusions: Induction of early remission using IFX appeared to be more effective in reducing background vascular leakage and in maintaining good visual acuity in BD patients.